Sign Up to like & get recommendations! 1
Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4719
Abstract: To explore the diagnostic value of radiomics in differentiating between lung adenocarcinomas appearing as ground‐glass opacity nodules (GGO) with high‐ and low Ki‐67 expression levels. read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30881
Abstract: Multiregional analysis provided first indications for morphological and molecular heterogeneity in lung adenocarcinomas (ADCs), but comprehensive morpho‐molecular comparisons are still lacking. The purpose of our study was to investigate the spatial distribution of EGFR and… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Clinical imaging"
DOI: 10.1016/j.clinimag.2018.05.028
Abstract: Objectives: To describe the radiological phenotype of HER2-mutant lung cancers on CT at presentation. Methods: Eligible patients with lung adenocarcinomas with HER2 mutations were stage-matched with two control groups (EGFR- and KRAS-mutant groups). Evaluated CT… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Clinical radiology"
DOI: 10.1016/j.crad.2018.01.009
Abstract: AIM To compare computed tomography (CT) radiogenomic and clinical characteristics between patients with epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS) mutations in lung adenocarcinomas. MATERIALS AND METHODS This study was… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Cancer treatment and research"
DOI: 10.1016/j.ctarc.2017.06.006
Abstract: Abstract Introduction Prior studies have shown that the activation of epithelio-mesenchymal transition (EMT) in tumor cells induces their invasive and metastatic properties. In our study, we aimed to elucidate the clinicopathologic significance of EMT in… read more here.
Sign Up to like & get recommendations! 1
Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.03.015
Abstract: OBJECTIVES Thyroid transcription factor 1 (TTF-1) is routinely tested in the diagnostic evaluation of suspected lung cancers, is commonly expressed by lung adenocarcinomas, and may modulate lung cancer biology. We examined the role of TTF-1… read more here.
Sign Up to like & get recommendations! 1
Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.10.007
Abstract: OBJECTIVES Contrasting other EGFR mutations (EGFRm) in lung adenocarcinomas, insertions in exon 20 (exon20ins) are generally associated with resistance to targeted therapy, limiting therapeutic options and impoverishing the prognosis compared to other EGFRm. We sought… read more here.
Sign Up to like & get recommendations! 1
Published in 2017 at "Oncogene"
DOI: 10.1038/onc.2016.524
Abstract: TTF-1, also known as NKX2-1, is a transcription factor that has indispensable roles in both lung development and physiology. We and others have reported that TTF-1 frequently exhibits high expression with increased copy number in… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-70316-3
Abstract: The aim of this study was to develop and test multiclass predictive models for assessing the invasiveness of individual lung adenocarcinomas presenting as subsolid nodules on computed tomography (CT). 227 lung adenocarcinomas were included: 31… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.465
Abstract: Although lung adenocarcinomas frequently metastasize to the brain, treatment options for lung adenocarcinoma brain metastases are limited. We discovered novel candidate drivers of progression by using case-control analyses to compare whole-exome sequencing data from a… read more here.
Sign Up to like & get recommendations! 1
Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13128
Abstract: To investigate the prognostic impact of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement for the overall survival (OS) of patients with surgically treated lung adenocarcinomas. read more here.